Micobiomed

MiCo BioMed (formerly RollingStone Co., Ltd.) is a South Korean point-of-care testing (POCT) diagnostics company specializing in molecular diagnostics, immunodiagnostics, and biochemical diagnostics. Headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company develops and manufactures the VERI-Q family of in-vitro diagnostic devices, including real-time PCR systems, LabChip-based microfluidic platforms, and rapid immunoassay kits for COVID-19 and other diseases. Its core products include the Veri-Q PCR 316 system, LabChip_16CH (a 16-channel microfluidic lab-on-a-chip), VERI-Q PREP M16 nucleic acid extraction system, and VERI-Q biochemical analyzers for glucose and hemoglobin monitoring. The company integrates molecular, immunological, and biochemical diagnostic technologies to create compact POCT devices deployable in clinical and field settings. MiCo BioMed has received investment from Trinity Biotech and expanded internationally, including a partnership with Institut Pasteur de Dakar.